Concepedia

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin

Daniel Tatosian, Ying Guo, Andrea Schaeffer, Natalia Gaibu, Serghei Popa, Aubrey Stoch, Ronald B. Langdon, Eunkyung Kauh

Diabetes Therapy · 2013 · 47 citations · 16 references

DOIFull text

Open access

Abstract

Once daily treatment with sitagliptin provided trough DPP-4 inhibition significantly greater than saxagliptin or vildagliptin administered once daily, and similar to that provided by vildagliptin administered twice daily.

References

16

Small Sample Inference for Fixed Effects from Restricted Maximum Likelihood

Michael G. Kenward, James Roger · Biometrics · 1997 · 4.4K citations

, , +12

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

Gary Herman, Arthur Bergman, Catherine Stevens et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 498 citations

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

Stacey Conarello, Zhihua Li, John Ronan et al. · Proceedings of the National Academy of Sciences · 2003 · 348 citations · Full text

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

Daniel J. Drucker, Steven I. Sherman, Fred S. Gorelick et al. · Diabetes Care · 2010 · 308 citations · Full text

, , +15

Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes

Maria Rosaria Rizzo, Michelangela Barbieri, Raffaele Marfella et al. · Diabetes Care · 2012 · 308 citations · Full text